Ana Lacerda

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8

International Standards for Pediatric Palliative Care: From IMPaCCT to GO-PPaCS

Franca Benini, Danai Papadatou, Mercedes Bernadá et al. · Journal of Pain and Symptom Management · 2022 · 280 citations · Full text

Medicine, Child Health, Pediatrics +10

Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without <i>MYCN</i> Gene Amplification

Bruno De Bernardi, Mary Gerrard, Luca Boni et al. · Journal of Clinical Oncology · 2009 · 138 citations

Medicine, Oncology, Pediatrics +17

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group

Bruno De Bernardi, Véronique Mosseri, H Rubie et al. · British Journal of Cancer · 2008 · 132 citations · Full text

Medicine, Surgery, Neoplasia +5

Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study

Ruth Ladenstein, Dominique Valteau‐Couanet, Penelope Brock et al. · Journal of Clinical Oncology · 2010 · 132 citations

Medicine, Oncology, Pediatrics +15